Amylin said it is seeking a preliminary and permanent injunction in its complaint. Amylin alleges that Lilly is engaging in improper, unlawful and anticompetitive behavior in the manner in which it plans to implement its recently announced global alliance with Boehringer Ingelheim to jointly develop and commercialize its linagliptin product, which will compete directly with exenatide.
via forbes.com
No comments:
Post a Comment